Summary:
- PAVmed (PAVM, Financial) plans to offer 3.3 million shares of common stock as part of its strategic growth initiatives.
- Analysts project an average price target of $11.50, indicating significant potential upside from the current stock price.
- The company's Veris implantable device submission is anticipated by 2025, enhancing its growth prospects.
PAVmed Inc. (PAVM) is making significant strides with its decision to issue 3.3 million shares of common stock. This strategic move aligns with the company’s broader objectives, including a pivotal submission for its innovative Veris implantable device expected by 2025.
Wall Street Analysts Forecast
According to the one-year price targets from two analysts, PAVmed Inc. (PAVM, Financial) holds an average target price of $11.50. This reflects a substantial upside potential of 1,811.89% from the current price of $0.60. Analysts’ projections range widely, from a low estimate of $4.00 to a high of $19.00. Investors can explore more detailed projections on our PAVmed Inc (PAVM) Forecast page.
The consensus from two brokerage firms rates PAVmed at 2.0, categorizing it as "Outperform.” This rating scale ranges from 1, indicating a Strong Buy, to 5, signifying a Sell.
GuruFocus's GF Value Estimate
Our proprietary GF Value estimate for PAVmed Inc (PAVM, Financial) suggests a fair stock value of $7.82 over the next year. This implies a remarkable upside of 1200.08% from its current price of $0.6015. The GF Value is rooted in historical trading multiples, previous business growth trends, and forecasts for future performance. For more comprehensive data, visit the PAVmed Inc (PAVM) Summary page.
